Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 4/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | NPC1 | O15118 | 3/20 | 0.45 |
| ▸ | RAB9A | P51151 | 3/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | AR | P10275 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.45 |
| ▸ | GFER | P55789 | 1/20 | 0.45 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.45 |
| ▸ | RELA | Q04206 | 1/20 | 0.45 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.45 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.45 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.41 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2126907 | 0.87 | CYP1A2 (0.60) | CYP1A2SMN1; SMN2ALDH1A1NPC1RAB9A | |
| SCHEMBL27908366 | 0.85 | CYP1A2 (0.58) | CYP1A2SMN1; SMN2ALDH1A1NPC1RAB9A | |
| SCHEMBL18731739 | 0.81 | CYP1A1 (0.66) | CYP1A2SMN1; SMN2ALDH1A1NPC1RAB9A | |
| SCHEMBL23008424 | 0.80 | CYP1A1 (0.64) | CYP1A2SMN1; SMN2ALDH1A1NPC1RAB9A | |
| SCHEMBL14725249 | 0.80 | CYP1A1 (0.54) | CYP1A2SMN1; SMN2ALDH1A1NPC1RAB9A | |
| SCHEMBL20137316 | 0.79 | ASIC3 (0.55) | CYP1A2SMN1; SMN2ALDH1A1NPC1RAB9A | |
| SCHEMBL632053 | 0.79 | ASIC3 (0.59) | CYP1A2SMN1; SMN2ALDH1A1NPC1RAB9A | |
| SCHEMBL29392239 | 0.79 | ASIC3 (0.59) | CYP1A2SMN1; SMN2ALDH1A1NPC1RAB9A | |
| SCHEMBL13934776 | 0.79 | CYP1A2 (0.47) | CYP1A2SMN1; SMN2ALDH1A1NPC1RAB9A | |
| SCHEMBL16659314 | 0.79 | KMO (0.57) | CYP1A2SMN1; SMN2NPC1RAB9AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9985223-B2 | Iridium organometallic complexes comprising 4-arylpyrimidines | SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) | 2018-05-29 | — | — | US | disclosed |
| US-9985223-B2 | Iridium organometallic complexes comprising 4-arylpyrimidines | SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) | 2018-05-29 | — | — | US | disclosed |
| US-9985223-B2 | Iridium organometallic complexes comprising 4-arylpyrimidines | SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) | 2018-05-29 | — | — | US | disclosed |
| US-20160064678-A1 | Organometallic Complex, Light-Emitting Element, Light-Emitting Device, Electronic Device and Lighting Device | SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) | 2016-03-03 | — | — | US | disclosed |
| US-20160064678-A1 | Organometallic Complex, Light-Emitting Element, Light-Emitting Device, Electronic Device and Lighting Device | SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) | 2016-03-03 | — | — | US | disclosed |
| US-20160064678-A1 | Organometallic Complex, Light-Emitting Element, Light-Emitting Device, Electronic Device and Lighting Device | SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) | 2016-03-03 | — | — | US | disclosed |
| US-9184398-B2 | Light-emitting elements comprising iridium organometallic complexes comprising 4-arylpyrimidines | SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) | 2015-11-10 | — | — | US | disclosed |
| US-9184398-B2 | Light-emitting elements comprising iridium organometallic complexes comprising 4-arylpyrimidines | SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) | 2015-11-10 | — | — | US | disclosed |
| US-9184398-B2 | Light-emitting elements comprising iridium organometallic complexes comprising 4-arylpyrimidines | SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) | 2015-11-10 | — | — | US | disclosed |
| US-20150108462-A1 | Organometallic Complex, Light-Emitting Element, Light-Emitting Device, Electronic Device and Lighting Device | SEMICONDUCTOR ENERGY LAB (JP) | 2015-04-23 | — | — | US | disclosed |
| EP-2190824-A1 | NAPHTHYLPYRIMIDINE, NAPHTHYLPYRAZINE AND NAPHTHYLPYRIDAZINE ANALOGS AND THEIR USE AS AGONISTS OF THE WNT-BETA-CATENIN CELLULAR MESSAGING SYSTEM | Wyeth a Corporation of the State of Delaware (US) | 2010-06-02 | — | — | EP | disclosed |
| WO-2010020432-A8 | COMPOUNDS FOR TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | BIOMARIN IGA LIMITED (BS) | 2010-03-11 | — | — | WO | disclosed |
| WO-2010020432-A2 | COMPOUNDS FOR TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | SUMMIT CORPORATION PLC (GB) | 2010-02-25 | — | — | WO | disclosed |
| US-20090054392-A1 | NAPHTHYLPYRIMIDINE, NAPHTHYLPYRAZINE AND NAPHTHYLPYRIDAZINE ANALOGS AND THEIR USE AS AGONISTS OF THE WNT-BETA-CATENIN CELLULAR MESSAGING SYSTEM | WYETH (US) | 2009-02-26 | — | — | US | disclosed |
| US-20090054392-A1 | NAPHTHYLPYRIMIDINE, NAPHTHYLPYRAZINE AND NAPHTHYLPYRIDAZINE ANALOGS AND THEIR USE AS AGONISTS OF THE WNT-BETA-CATENIN CELLULAR MESSAGING SYSTEM | WYETH (US) | 2009-02-26 | — | — | US | disclosed |
| WO-2009026326-A1 | NAPHTHYLPYRIMIDINE, NAPHTHYLPYRAZINE AND NAPHTHYLPYRIDAZINE ANALOGS AND THEIR USE AS AGONISTS OF THE WNT-BETA-CATENIN CELLULAR MESSAGING SYSTEM | WYETH (US) | 2009-02-26 | — | — | WO | disclosed |
| WO-2009026319-A1 | NAPHTHYLPYRIMIDINE, NAPHTHYLPYRAZINE AND NAPHTHYLPYRIDAZINE ANALOGS AND THEIR USE AS AGONISTS OF THE WNT-BETA-CATENIN CELLULAR MESSAGING SYSTEM | WYETH (US) | 2009-02-26 | — | — | WO | disclosed |
| WO-2009026326-A1 | NAPHTHYLPYRIMIDINE, NAPHTHYLPYRAZINE AND NAPHTHYLPYRIDAZINE ANALOGS AND THEIR USE AS AGONISTS OF THE WNT-BETA-CATENIN CELLULAR MESSAGING SYSTEM | WYETH (US) | 2009-02-26 | — | — | WO | disclosed |
| WO-2009026319-A1 | NAPHTHYLPYRIMIDINE, NAPHTHYLPYRAZINE AND NAPHTHYLPYRIDAZINE ANALOGS AND THEIR USE AS AGONISTS OF THE WNT-BETA-CATENIN CELLULAR MESSAGING SYSTEM | WYETH (US) | 2009-02-26 | — | — | WO | disclosed |
| US-20090054392-A1 | NAPHTHYLPYRIMIDINE, NAPHTHYLPYRAZINE AND NAPHTHYLPYRIDAZINE ANALOGS AND THEIR USE AS AGONISTS OF THE WNT-BETA-CATENIN CELLULAR MESSAGING SYSTEM | WYETH (US) | 2009-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054392-A1 | NAPHTHYLPYRIMIDINE, NAPHTHYLPYRAZINE AND NAPHTHYLPYRIDAZINE ANALOGS AND THEIR USE AS AGONISTS OF THE WNT-BETA-CATENIN CELLULAR MESSAGING SYSTEM | WNT1, CTNNB1, WNT3A | CYP1A2 2520/4885SMN1; SMN2 1750/4885ALDH1A1 2250/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.